Literature DB >> 14581137

Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid.

Yoshiko Hisamatsu1, Toshio Nishiyama, Satoshi Amano, Chihiro Matsui, Riza Ghohestani, Takashi Hashimoto.   

Abstract

BACKGROUND: Anti-laminin 5 cicatricial pemphigoid (CP) is a mucosal-dominant subepithelial blistering disease characterized by IgG anti-basement membrane zone autoantibodies, that bind to dermal side of 1 M NaCl split skin and immunoprecipitate laminin 5. Laminin 5 is an epidermis-specific extracellular matrix consisting of alpha3, beta3 and gamma2 subunits. Recent studies have suggested that autoantibodies of anti-laminin 5 CP recognize the G domains of alpha3 subunit.
OBJECTIVE: We examined the reactivity of anti-laminin 5 CP by immunoblotting using purified laminin 5 and recombinant proteins of alpha3 subunit.
METHOD: We first examined the reactivity of anti-laminin 5 CP by immunoblotting using purified laminin 5. To further investigate the epitopes in the G domains of alpha3 subunit, we produced recombinant proteins of G1-2, G1-3, G2-3, G3-5 domains, that covered entire G domain, and examined the reactivity of anti-laminin 5 CP sera with these recombinant proteins by immunoblotting.
RESULTS: By immunoblotting using purified laminin 5, 7 of 21 anti-laminin 5 CP sera reacted with alpha3 subunit, while 8 sera reacted with beta3 subunit and one serum reacted with gamma2 subunit. Two sera reacted with both alpha3 and beta3 subunits, while seven sera did not show positive reactivity. This result indicates that the reactivity of anti-laminin 5 CP sera is much more heterogeneous, although the previous studies suggested that most sera reacted with alpha3 subunit. However, in the studies using recombinant proteins of G domains of alpha3 subunit, none of the CP sera, including the sera reactive with alpha3 subunit in purified laminin 5, reacted with any recombinant proteins. The reason for this negative reactivity with the recombinant proteins is not clear.
CONCLUSION: The immunoblotting using purified laminin 5 should be useful technique for the diagnosis of anti-laminin 5 CP, although the sensitivity was less than conventional immunoprecipitation analysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581137     DOI: 10.1016/s0923-1811(03)00158-0

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  10 in total

1.  Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.

Authors:  Helen Kaipe; Lena-Maria Carlson; Tom Erkers; Silvia Nava; Pia Molldén; Britt Gustafsson; Hua Qian; Xiaoguang Li; Takashi Hashimoto; Behnam Sadeghi; Mats Alheim; Olle Ringdén
Journal:  Stem Cells Dev       Date:  2015-03-13       Impact factor: 3.272

2.  Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis.

Authors:  Eijiro Akasaka; Sato-Jin Kayo; Hajime Nakano; Norito Ishii; Takashi Hashimoto; Daisuke Sawamura
Journal:  Case Rep Dermatol       Date:  2015-07-25

3.  Molecular diagnosis of anti-laminin 332 (epiligrin) mucous membrane pemphigoid.

Authors:  Roxana Chiorean; Sorina Danescu; Oana Virtic; Mayson B Mustafa; Adrian Baican; Annette Lischka; Takashi Hashimoto; Yoshinobu Kariya; Manuel Koch; Cassian Sitaru
Journal:  Orphanet J Rare Dis       Date:  2018-07-06       Impact factor: 4.123

Review 4.  Serological Diagnosis of Autoimmune Bullous Skin Diseases.

Authors:  Sandra Saschenbrecker; Ingolf Karl; Lars Komorowski; Christian Probst; Cornelia Dähnrich; Kai Fechner; Winfried Stöcker; Wolfgang Schlumberger
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

5.  Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option.

Authors:  Franziska Schauer; Norito Ishii; Maja Mockenhaupt; Leena Bruckner-Tuderman; Takashi Hashimoto; Dimitra Kiritsi
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561

6.  Keratinocyte footprint assay discriminates antilaminin-332 pemphigoid from all other forms of pemphigoid diseases.

Authors:  F Giurdanella; A M Nijenhuis; G F H Diercks; M F Jonkman; H H Pas
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

7.  Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid.

Authors:  Stephanie Goletz; Federica Giurdanella; Maike M Holtsche; Miranda Nijenhuis; Barbara Horvath; Gilles F H Diercks; Detlef Zillikens; Takashi Hashimoto; Enno Schmidt; Hendri H Pas
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

8.  A Case of IgG and IgA Anti-Laminin-332 Antibody-Positive Mucous Membrane Pemphigoid with IgG and IgA Anti-Envoplakin and Anti-Periplakin Antibodies.

Authors:  Yoshiaki Matsushima; Masako Kitano; Daisuke Hayashi; Hiroyuki Goto; Mako Mine; Takeshi Yokoe; Makoto Kondo; Koji Habe; Yuji Toiyama; Takashi Hashimoto; Daisuke Tsuruta; Kazuhiko Takeuchi; Keiichi Yamanaka
Journal:  Dermatopathology (Basel)       Date:  2022-08-08

9.  Clinical and Immunological Study of 30 Cases With Both IgG and IgA Anti-Keratinocyte Cell Surface Autoantibodies Toward the Definition of Intercellular IgG/IgA Dermatosis.

Authors:  Takashi Hashimoto; Kwesi Teye; Koji Hashimoto; Katarzyna Wozniak; Daisuke Ueo; Sakuhei Fujiwara; Kazuhiro Inafuku; Yorihisa Kotobuki; Ines Lakos Jukic; Branka Marinović; Anna Bruckner; Daisuke Tsuruta; Tamihiro Kawakami; Norito Ishii
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

10.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.